Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
F DuffaudW T A van der Graaf

Abstract

Reliable biomarkers of pazopanib's efficacy in soft tissue sarcoma (STS) are lacking. Hypertension (HTN) is an on-target effect of vascular endothelial growth factor (VEGF)-receptor inhibitors such as pazopanib. We evaluated the association of pazopanib-induced HTN with antitumour efficacy in patients with metastatic non-adipocytic STS. Associations between pazopanib-induced-HTN and antitumour efficacy were retrospectively assessed across 2 prospective studies (European Organisation for Research and Treatment of Cancer (EORTC) study 62043 and 62072) in metastatic STS patients who received pazopanib 800 mg daily. Only patients with baseline blood pressure (BP)<150/90 mmHg, were included. BP was measured monthly. HTN was reported according to National Cancer Institute-Common Toxicity Criteria Adverse Events (NCI-CTC AE) grading (v3.0), and as absolute differences compared to baseline. The effect of HTN developing in patients without baseline anti-hypertensive medication was assessed on progression-free (PFS) and overall survival (OS) using a landmark analysis stratified by study; univariately using the Kaplan-Meier method and a log-rank test, and in a multivariate Cox regression model after adjustment for important prognostic fac...Continue Reading

References

Jul 28, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S S YoonS Singer
Dec 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert C KaneRichard Pazdur
Jun 26, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O RixeH Izzedine
Nov 7, 2008·The Oncologist·Stefan SleijferJean-Yves Blay
Aug 4, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S GeorgeG D Demetri

❮ Previous
Next ❯

Citations

Nov 28, 2017·Clinical and Experimental Hypertension : CHE·Amber KemptonSakima A Smith
Jul 9, 2020·International Journal of Cancer. Journal International Du Cancer·Yoshihiro NishidaAkira Kawai
Aug 25, 2016·Expert Opinion on Drug Metabolism & Toxicology·Pascaline Boudou-RouquetteFrançois Goldwasser
Apr 24, 2018·Japanese Journal of Clinical Oncology·Shingo MiyamotoAkira Ishikawa
May 28, 2019·Signal Transduction and Targeted Therapy·Alex T J LeePaul H Huang
Feb 12, 2017·Clinical Pharmacokinetics·Remy B VerheijenNeeltje Steeghs
Aug 11, 2017·Therapeutic Advances in Medical Oncology·Gino K InWilliam W Tseng
May 1, 2018·Journal of Cardiovascular Pharmacology and Therapeutics·Cody N JusticeSakima A Smith
Feb 13, 2018·Therapeutic Advances in Medical Oncology·Arduino A MangoniMichael J Sorich
Feb 2, 2019·Current Vascular Pharmacology·Cecilie BudolfsenNils Erik Magnusson
May 18, 2020·Signal Transduction and Targeted Therapy·Alex T J LeePaul H Huang
Apr 2, 2021·Circulation Research·Daan C H van DorstNinian N Lang
Apr 25, 2021·Pediatric Blood & Cancer·Marissa A JustLars M Wagner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.